Evaxion Biotech Files 6-K, Incorporates by Reference

TL;DR

EVX files 6-K, rolls into existing S-8/F-3/F-1 filings. Standard reporting.

AI Summary

Evaxion Biotech A/S filed a Form 6-K on January 21, 2025, for the month of January 2025. This report is for a foreign private issuer and is incorporated by reference into several of Evaxion's existing registration statements on Forms S-8 and F-3, as well as multiple F-1 filings. The company is based in Hoersholm, Denmark.

Why It Matters

This filing indicates ongoing reporting obligations and the integration of this report into previous securities offerings, suggesting continued activity and compliance for investors.

Risk Assessment

Risk Level: low — This is a routine filing for a foreign private issuer, primarily for incorporation by reference into existing registration statements, and does not appear to contain new material information or significant corporate events.

Key Numbers

• 001-39950 — Commission File Number (Identifies the specific SEC filing record for Evaxion Biotech A/S.)

Key Players & Entities

• Evaxion Biotech A/S (company) — Registrant
• 001-39950 (dollar_amount) — Commission File Number
• 333-255064 (dollar_amount) — Form S-8 File Number
• 333-265132 (dollar_amount) — Form F-3 File Number
• 333-266050 (dollar_amount) — Form F-1 File Number
• 333-276505 (dollar_amount) — Form F-1 File Number
• 333-279153 (dollar_amount) — Form F-1 File Number
• 333-283304 (dollar_amount) — Form F-1 File Number

FAQ

From the Filing

0001171843-25-000332.txt : 20250121 0001171843-25-000332.hdr.sgml : 20250121 20250121061607 ACCESSION NUMBER: 0001171843-25-000332 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20250120 FILED AS OF DATE: 20250121 DATE AS OF CHANGE: 20250121 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Evaxion Biotech A/S CENTRAL INDEX KEY: 0001828253 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: G7 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39950 FILM NUMBER: 25540328 BUSINESS ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 BUSINESS PHONE: 004531262615 MAIL ADDRESS: STREET 1: DR NEERGAARDS VEJ 5F CITY: HOERSHOLM STATE: G7 ZIP: 2970 6-K 1 f6k_012025.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 6-K       REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO SECTION 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-39950       Evaxion Biotech A/S (Exact Name of Registrant as Specified in Its Charter)   Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ 	Form 40-F ☐     INCORPORATION BY REFERENCE This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion Biotech A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), and Form F-1 (File No. 333-283304), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.   Amendment to Articles of Association Evaxion Biotech A/S (the “Company”) registered share capital increases in aggregate nominal DKK 8,510,000 ordinary shares with the Danish Business Authority, with effective dates January 7 and January 15, 2025, corresponding to an aggregate increase in the Company’s share capital to nominal DKK 78,640,556, in connection with the exercise of pre-funded warrants conferring the right to subscribe at an exercise price of $1.4537 per ADS with the terms set forth in detail on appendix 7 of the Articles of Association. There are no remaining prefunded warrants issued under Appendix 7. The Company’s Articles of Association were amended as of January 7 and January 15, 2025, to reflect this capital increase and are attached hereto as Exhibit 1.1. Extraordinary General Meeting - Resolutions passed at the Extraordinary General Meeting On January 17, 2025, at 3:00 p.m. (CEST), the Company held an Extraordinary General Meeting (sometimes referred to herein as the “General Meeting”), at the Company’s registered offices located at Dr Neergaards Vej 5F, 2970 Hørsholm, Denmark, at which 15,308,584 ordinary shares of the Company representing in total 20.1% of the ordinary shares outstanding as of the date of the General Meeting were voted at the meeting. The final results of each of the agenda items submitted to a vote of the shareholders are as follows: Agenda Item 1: Election of the chairman of the meeting Attorney-at-law Lars Lüthjohan was elected as chairman of the meeting with the required majority.   The chairman informed the shareholders that due to increases in the share capital in the period from the date of the notice (20 December 2024) and date of the General Me